IDEAYA Biosciences to Participate in Investor Conferences in March 2023

SOUTH SAN FRANCISCO, Calif., March 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in March 2023.

Oppenheimer 33rd Annual Healthcare Conference
Tuesday, March 14th, 2023 at 1:20 PM ET

- Fireside chat with Michael White, Chief Scientific Officer and Darrin Beaupre, Chief Medical Officer, hosted by Matthew Biegler, Executive Director and Senior Analyst

Guggenheim 4th Annual Healthy Altitudes Summit
Wednesday, March 15th, 2023 at 9:15 AM ET

- Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Charles Zhu, Ph.D. Vice President and Equity Research Analyst

A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events. A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on August 15, 2022 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com

SOURCE IDEAYA Biosciences, Inc.
